CL2015003200A1 - Potenciador de inhibidores del homólogo de zeste - Google Patents

Potenciador de inhibidores del homólogo de zeste

Info

Publication number
CL2015003200A1
CL2015003200A1 CL2015003200A CL2015003200A CL2015003200A1 CL 2015003200 A1 CL2015003200 A1 CL 2015003200A1 CL 2015003200 A CL2015003200 A CL 2015003200A CL 2015003200 A CL2015003200 A CL 2015003200A CL 2015003200 A1 CL2015003200 A1 CL 2015003200A1
Authority
CL
Chile
Prior art keywords
zeste
counterpart
inhibitor enhancer
ezh2
enhancer
Prior art date
Application number
CL2015003200A
Other languages
English (en)
Inventor
Jr Charles William Blackledge
Joelle Lorraine Burgess
Neil W Johnson
Jiri Kasparec
Steven David Knight
Iii Louis V Lafrance
Juan I Luengo
William Henry Miller
Kenneth Allen Newlander
Stuart Paul Romeril
Mark Schulz
Dai-Shi Su
Xinrong Tian
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of CL2015003200A1 publication Critical patent/CL2015003200A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

COMPUESTOS DERIVADOS DE N-((2-OXO-1,2-DIHIDROPIRIDIN-3-IL)METIL)-CARBOXAMIDA, INHIBIDORES DEL POTENCIADOR DEL HOMOLOGO ZESTE 2 (EZH2); COMPOSICION FARMACEUTICA QUE LOS COMPRENDE; METODO PARA TRATAR CANCER; Y SU USO PARA EL TRATAMIENTO DE UN TRASTORNO MEDIADO POR EZH2.
CL2015003200A 2013-04-30 2015-10-30 Potenciador de inhibidores del homólogo de zeste CL2015003200A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361817436P 2013-04-30 2013-04-30
US201361842038P 2013-07-02 2013-07-02
US201361907024P 2013-11-21 2013-11-21
US201461936460P 2014-02-06 2014-02-06

Publications (1)

Publication Number Publication Date
CL2015003200A1 true CL2015003200A1 (es) 2016-04-22

Family

ID=50877537

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003200A CL2015003200A1 (es) 2013-04-30 2015-10-30 Potenciador de inhibidores del homólogo de zeste

Country Status (20)

Country Link
US (2) US9505745B2 (es)
EP (1) EP2991980B1 (es)
JP (1) JP6373973B2 (es)
KR (1) KR20160003115A (es)
CN (1) CN105308038B (es)
AU (1) AU2014261075B2 (es)
BR (1) BR112015027527A2 (es)
CA (1) CA2910873A1 (es)
CL (1) CL2015003200A1 (es)
DO (1) DOP2015000270A (es)
EA (1) EA030196B1 (es)
ES (1) ES2717680T3 (es)
HK (1) HK1214815A1 (es)
MX (1) MX2015015144A (es)
NZ (1) NZ630205A (es)
PE (1) PE20151981A1 (es)
PH (1) PH12015502414A1 (es)
SG (1) SG11201508203TA (es)
WO (1) WO2014177982A1 (es)
ZA (1) ZA201507398B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2862289C (en) * 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
KR102021642B1 (ko) 2012-10-15 2019-09-16 에피자임, 인코포레이티드 암을 치료하는 방법
US9505745B2 (en) * 2013-04-30 2016-11-29 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
EP3019494B1 (en) 2013-07-10 2017-06-21 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
EP3102568B1 (en) 2014-02-06 2018-06-27 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists.
CN107148419A (zh) * 2014-10-28 2017-09-08 葛兰素史密斯克莱知识产权（第2 号）有限公司 Zeste增强子同源物2抑制剂
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
UY36758A (es) * 2015-06-30 2016-12-30 Glaxosmithkline Ip No 2 Ltd Inhibidores del potenciador del homólogo zeste 2
CN108025191A (zh) 2015-08-24 2018-05-11 Epizyme股份有限公司 治疗癌症的方法
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
US20190070188A1 (en) * 2015-11-06 2019-03-07 Epizyme, Inc. Pediatric dosing for treatment of cancer with an ezh2 inhibitor
WO2017084494A1 (zh) 2015-11-19 2017-05-26 江苏恒瑞医药股份有限公司 苯并呋喃类衍生物、其制备方法及其在医药上的应用
MX2018013519A (es) * 2016-05-05 2019-03-14 Glaxosmithkline Ip No 2 Ltd Inhibidores del potenciador del homologo zeste 2.
US20170337814A1 (en) * 2016-05-20 2017-11-23 Donald Edward Morgan Safety alerting drivers device and system
AU2017323112B2 (en) 2016-09-07 2020-11-26 Haihe Biopharma Co., Ltd. Pyrido five-element aromatic ring compound, preparation method therefor and use thereof
WO2018125983A1 (en) 2016-12-30 2018-07-05 Mitobridge, Inc. Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
NZ766447A (en) 2018-01-31 2021-12-24 Mirati Therapeutics Inc Prc2 inhibitors
JP2021531340A (ja) 2018-07-09 2021-11-18 フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles 眼障害を治療するためのｐｒｃ２サブユニットの阻害
JP7624404B2 (ja) 2019-04-22 2025-01-30 ミラティ セラピューティクス，インク． Ｐｒｃ２阻害剤としてのナフチリジン誘導体
CN113544130B (zh) * 2019-05-31 2024-01-09 西藏海思科制药有限公司 一种btk抑制剂环衍生物及其制备方法和药学上的应用
AU2020288563A1 (en) 2019-06-05 2022-01-06 Mirati Therapeutics, Inc. Imidazo(1,2-c)pyrimidine derivatives as PRC2 inhibitors for treating cancer
CN114555112A (zh) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
CN110964200A (zh) * 2019-12-19 2020-04-07 新纳奇材料科技江苏有限公司 一种基于聚硅氧烷馏出物的羟基封端聚硅氧烷的制备方法
WO2021129629A1 (zh) * 2019-12-23 2021-07-01 四川海思科制药有限公司 Zeste增强子同源物2抑制剂及其用途
CN111233768B (zh) * 2020-03-18 2021-08-03 徐州圣元化工有限公司 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法
KR20250040894A (ko) 2022-05-25 2025-03-25 이케나 온콜로지, 인코포레이티드 Mek 억제제 및 이의 용도

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074642A2 (en) * 2004-01-30 2005-08-18 Smithkline Beecham Corporation Chemical compounds
CN1989131A (zh) * 2004-03-30 2007-06-27 希龙公司 取代的噻吩衍生物用作抗癌药
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
AU2006325746A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
BR112012002336A2 (pt) * 2009-08-07 2016-05-31 Merck Patent Gmbh compostos aza-heterocíclicos
ES2528269T3 (es) 2010-05-07 2015-02-06 Glaxosmithkline Llc Azaindazoles
US8536179B2 (en) 2010-05-07 2013-09-17 Glaxosmithkline Llc Indoles
WO2011140325A1 (en) * 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
US8765792B2 (en) 2010-12-01 2014-07-01 Glaxosmithkline Llc Indoles
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
BR112014007603A2 (pt) * 2011-09-30 2017-06-13 Glaxosmithkline Llc métodos de tratamento do câncer
CA2862289C (en) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
DK3628670T3 (da) 2012-04-13 2022-12-05 Epizyme Inc Saltform til ezh2-hæmning
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
US9505745B2 (en) * 2013-04-30 2016-11-29 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors

Also Published As

Publication number Publication date
JP2016517878A (ja) 2016-06-20
DOP2015000270A (es) 2016-02-15
ZA201507398B (en) 2017-01-25
MX2015015144A (es) 2016-02-18
HK1214815A1 (zh) 2016-08-05
EA201592068A1 (ru) 2016-05-31
PH12015502414A1 (en) 2016-02-22
SG11201508203TA (en) 2015-11-27
EP2991980A1 (en) 2016-03-09
PE20151981A1 (es) 2016-01-14
JP6373973B2 (ja) 2018-08-15
US20160102083A1 (en) 2016-04-14
US20170029412A1 (en) 2017-02-02
CN105308038A (zh) 2016-02-03
NZ630205A (en) 2017-03-31
CA2910873A1 (en) 2014-11-06
KR20160003115A (ko) 2016-01-08
US9790212B2 (en) 2017-10-17
BR112015027527A2 (pt) 2017-07-25
EA030196B1 (ru) 2018-07-31
WO2014177982A1 (en) 2014-11-06
AU2014261075A1 (en) 2015-11-05
CN105308038B (zh) 2018-05-29
ES2717680T3 (es) 2019-06-24
US9505745B2 (en) 2016-11-29
AU2014261075B2 (en) 2017-01-19
EP2991980B1 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
CL2019001711A1 (es) Composiciones y métodos para inhibir la acción de la arginasa.
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
CO2018004124A2 (es) Compuestos heterocíclicos
DOP2017000151A (es) Derivados de quinazolina utilizados para tratar el vih
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
EA201891057A1 (ru) Композиции и способы для ингибирования активности аргиназы
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
MX373373B (es) Inhibidores de desmetilasa-1 específica de lisina.
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
CL2016001790A1 (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2.
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
MX2017002206A (es) Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos.
EA201591532A1 (ru) Ингибиторы carm1 и их применение
CL2015000944A1 (es) Compuestos de benceno sustituido
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112015029495A2 (pt) compostos heterocíclicos como inibidores da via de sinalização hedgehog
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
MX2017011018A (es) Inhibicion de la actividad de olig2.
BR112017022281A2 (pt) métodos para tratar câncer
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina